I would like to introduce myself. My name is Martin Shefsky. I am the President at Global Ibogaine Corp, a forward-thinking healthcare company committed to addressing one of the most critical health crises of our time – opioid addiction.
We are now offering a seed round opportunity that will be limited to US $500,000
Ibogaine is a naturally occurring psychoactive substance. Global Ibogaine Corp. is establishing a specialized rehabilitation center to leverage the therapeutic benefits of Ibogaine and our partnership with the only licensed pharmaceutical manufacturer of legally sourced Ibogaine under GMP standards.
Extensive research has demonstrated that Ibogaine can significantly reduce withdrawal symptoms and cravings in opioid addiction1 offering a promising pathway to recovery for those trapped in the cycle of addiction. Ibogaine has also been found to be effective in treating PTSD and Traumatic Brain Injuries (TBI)2.
Global Ibogaine’s mission is to provide a holistic, effective solution to opioid addiction, PTSD, and TBI’s. Our team of experienced professionals is pioneering a new Ibogaine treatment, administered in a safe, medical and supportive environment. Global Ibogaine Corp. is positioned at the forefront of an exciting new frontier that offers ground-breaking and scalable solutions for Opioid Use Disorder, PTSD, and TBI’s.
We are privileged to offer a unique investment opportunity in an emerging health care company with the potential to revolutionize the way that opioid addiction, PTSD, and TBI’s are addressed. These problems are among the weightiest challenges that society faces and comprise an enormous addressable market including large numbers of military veterans.
. The seed funds will be strategically utilized as follows:
· Pilot Study: Treat 10-15 patients with Ibogaine to validate the recent Stanford University Ibogaine study results.
· Due diligence: To be conducted on several identified properties in Jamaica for the development of the Rehab Centre according to the highest industry standards for patient care and treatment.
· Securing regulatory approvals. This effort is supported by our existing partnership with a licensed Pharmaceutical Manufacturer fully approved to handle controlled substances, including Ibogaine. We delivered the first legal shipment of Iboga from Gabon to our partner on January 5, 2024.
· Managing the regulatory process for R & D and treatment modalities.
· Consultants: Our staffing requirements will initially be met by way of consulting agreements with known experienced professionals, to contain operating expenses. These will include the Chief Executive Officer, Chief Medical Officer, Chief Regulatory Officer, Ibogaine Treatment Specialist and the Organic Chemist. All positions have been recruited and are ready to commence pending financing.
· Production and Distribution: Processing will be conducted at our partner’s facility where we will fund additional equipment to facilitate the production of pharmaceutical GMP standard Ibogaine HCL for distribution to all legal jurisdictions. Our goal is to ensure a reliable and legal supply for both our use and for other research and development
· Our partner has already been approved to manufacture and distribute controlled substances to the United States by way of DEA authorization. The pathways from Jamaica to the United States have already been established for other Schedule 1 drugs.
This seed round investment will advance Global Ibogaine Corp. to become a leader in offering groundbreaking solutions for Opioid Use Disorder, PTSD, and TBI’s.
We would be delighted to provide you with a presentation, detailed business plan, and other relevant documentation and to arrange a call with our team so you can learn more about our project and ask any questions you may have.
Although we firmly believe this seed round investment offers tremendous potential for capital appreciation, investing in Global Ibogaine Corp. goes beyond financial returns. It represents a unique opportunity to make a profound social impact, to change lives and contribute significantly to the fight against the opioid crisis, along with helping those suffering from PTSD and TBI’s.
Please let me know a convenient time for you to discuss this opportunity in detail over a call or a Zoom.
Thank you for considering our proposal. I look forward to your response.
Best regards,
Martin Shefsky
Global Ibogaine Corp.
1. Ten research studies, ranging from systematic and literary reviews to observational studies were analyzed and concluded the following: 1 month post ibogaine therapy, 50% of patients displaying no opioid use compared to 18% with buprenorphine.
usehttps://health.ucdavis.edu/nursing/news/Events/PDF/Other_presentations/The%20efficacy%20of%20ibogaine%20use%20in%20opioid%20use%20disorder%20compared%20to%20buprenorphine.pdf
2. A recent landmark study published by Nature Medicine (January 5, 2024) and conducted by Stanford University has brought to light the remarkable potential of Ibogaine in treating PTSD and Traumatic Brain Injuries (TBI), among military veterans. This study focused on 30 former Navy Seals and demonstrated the efficacy of Ibogaine in significantly improving symptoms related to TBI, PTSD, depression, and anxiety. The results were profound, showing a substantial improvement in both mental health and overall functioning of the participants. This research not only validates the therapeutic potential of Ibogaine but also opens up new avenues for treating various neurological and psychiatric conditions along with Opioid Use Disorder treatment. This Study by Stanford University not only aligns with our project's objectives but also solidifies the credibility and urgency of developing Ibogaine-based therapies.